FY2025 Earnings Estimate for LGND Issued By Zacks Small Cap

Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) – Investment analysts at Zacks Small Cap lifted their FY2025 EPS estimates for Ligand Pharmaceuticals in a research note issued to investors on Monday, December 16th. Zacks Small Cap analyst J. Vandermosten now expects that the biotechnology company will post earnings of $4.63 per share for the year, up from their previous estimate of $3.85. The consensus estimate for Ligand Pharmaceuticals’ current full-year earnings is $1.73 per share.

Several other research analysts have also recently commented on LGND. HC Wainwright restated a “buy” rating on shares of Ligand Pharmaceuticals in a research report on Wednesday, December 11th. Barclays increased their price objective on Ligand Pharmaceuticals from $150.00 to $160.00 and gave the stock an “overweight” rating in a report on Monday. Oppenheimer raised their target price on Ligand Pharmaceuticals from $135.00 to $147.00 and gave the company an “outperform” rating in a research report on Friday, November 8th. Royal Bank of Canada boosted their price target on Ligand Pharmaceuticals from $141.00 to $143.00 and gave the stock an “outperform” rating in a research report on Wednesday, December 11th. Finally, Benchmark raised their price target on Ligand Pharmaceuticals from $110.00 to $135.00 and gave the company a “buy” rating in a report on Friday, November 8th. Six investment analysts have rated the stock with a buy rating, According to MarketBeat.com, the stock currently has an average rating of “Buy” and an average target price of $147.00.

Ligand Pharmaceuticals Stock Down 0.4 %

LGND stock opened at $113.94 on Wednesday. The stock has a market cap of $2.15 billion, a PE ratio of 45.39 and a beta of 1.01. The firm’s 50-day simple moving average is $114.97 and its 200 day simple moving average is $102.92. Ligand Pharmaceuticals has a fifty-two week low of $67.53 and a fifty-two week high of $129.90.

Insiders Place Their Bets

In other Ligand Pharmaceuticals news, Director John L. Lamattina sold 2,406 shares of the business’s stock in a transaction dated Wednesday, November 27th. The shares were sold at an average price of $123.65, for a total value of $297,501.90. Following the sale, the director now directly owns 29,515 shares in the company, valued at approximately $3,649,529.75. The trade was a 7.54 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, insider Andrew Reardon sold 2,000 shares of the company’s stock in a transaction dated Monday, September 23rd. The shares were sold at an average price of $99.60, for a total transaction of $199,200.00. Following the completion of the sale, the insider now directly owns 22,534 shares of the company’s stock, valued at $2,244,386.40. The trade was a 8.15 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 14,178 shares of company stock worth $1,485,824 over the last ninety days. Company insiders own 5.90% of the company’s stock.

Institutional Inflows and Outflows

Institutional investors have recently modified their holdings of the stock. Principal Financial Group Inc. boosted its stake in shares of Ligand Pharmaceuticals by 5.0% during the 3rd quarter. Principal Financial Group Inc. now owns 93,208 shares of the biotechnology company’s stock worth $9,329,000 after acquiring an additional 4,439 shares in the last quarter. Franklin Resources Inc. lifted its holdings in shares of Ligand Pharmaceuticals by 503.5% during the third quarter. Franklin Resources Inc. now owns 94,659 shares of the biotechnology company’s stock valued at $9,793,000 after purchasing an additional 78,973 shares during the last quarter. Wilmington Savings Fund Society FSB acquired a new position in shares of Ligand Pharmaceuticals in the 3rd quarter valued at $180,000. Geode Capital Management LLC increased its stake in Ligand Pharmaceuticals by 5.5% in the 3rd quarter. Geode Capital Management LLC now owns 428,270 shares of the biotechnology company’s stock worth $42,874,000 after purchasing an additional 22,495 shares in the last quarter. Finally, Barclays PLC increased its stake in Ligand Pharmaceuticals by 20.0% in the 3rd quarter. Barclays PLC now owns 43,456 shares of the biotechnology company’s stock worth $4,349,000 after purchasing an additional 7,247 shares in the last quarter. Institutional investors own 91.28% of the company’s stock.

About Ligand Pharmaceuticals

Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, engages in the development and licensing of biopharmaceutical assets worldwide. Its commercial programs include Kyprolis and Evomela, which are used to treat multiple myeloma; Rylaze, a recombinant erwinia asparaginase for the treatment of acute lymphoblastic leukemia or lymphoblastic lymphoma in adult and pediatric patients; Filspari, a dual endothelin and angiotensin II receptor antagonist in development for rare kidney diseases and non-immunosuppressive treatment indicated for immunoglobulin A nephropathy; Teriparatide injection product for osteoporosis; Vaxneuvance for the prevention of invasive disease caused by streptococcus pneumoniae serotypes; and Pneumosil, a pneumococcal conjugate vaccine to help fight against pneumococcal pneumonia among children.